Cordis Corp.
Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.
Regulatory wins across continents for J&J’s Cordis
Cordis Corp., the stenting arm of Johnson & Johnson(NYSE:JNJ), announced regulatory wins in the U.S. and the E.U. for new sizes of its Sleek OTW balloon catheter, used to clear clogged arteries below the knee and prevent lower limb amputations.
J&J’s Cordis lands FDA win for next-gen Adroit guiding catheter
Cordis Corp., the stent-making division of Johnson & Johnson (NYSE:JNJ), landed a new U.S. regulatory win for its next-generation Adroit 6F Guiding Catheter, which the company said can handle more sophisticated cases than earlier versions.
J&J’s Cordis escapes $593M stent patent infringement loss
Johnson & Johnson (NYSE:JNJ) logged a major win for its Cordis stent-making arm today when a federal appeals court overturned a lower court decision to award more than $593 million to stent pioneer Dr. Bruce Saffran for patent infringement.
Saffran alleged that Cordis violated his patent with the Cypher drug-eluting stent, leading to a jury trial that went Saffran’s way.
Appeals court hands Abbott a win in stent patent battle with Johnson & Johnson’s Cordis
Abbott (NYSE:ABT) held on to a win in its patent infringement war with Johnson & Johnson‘s (NYSE:JNJ) Cordis Corp. after a federal appeals court upheld a lower court ruling last month.
MassDevice.com +7 | The top 7 med-tech stories for the week of March 11, 2013
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
J&J’s Cordis snaps up Flexible Stenting Solutions
Cordis Corp., the stent-making arm of healthcare colossus Johnson & Johnson (NYSE:JNJ), said it’s acquired Flexible Stenting Solutions as part of turning its back on the coronary stents market in favor of the endovascular arena.
When it comes to robots, opinions run hot
Legal: Boston Scientific notches a win in Cordis stent patent spat
A federal appeals court upheld a $41 million verdict for Boston Scientific over erstwhile arch-rival Cordis Corp., the Johnson & Johnson subsidiary that ceded the coronary stent market in 2011.
Cordis unveils 2-year trial results for S.M.A.R.T. vascular stent systems
Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. this week unveiled positive 2-year clinical trial results for its S.M.A.R.T. vascular stent systems in treatment of patients with obstructive superficial femoral artery disease.